XML 39 R8.htm IDEA: XBRL DOCUMENT

NATURE OF OPERATIONS

12 Months Ended

Mar. 31, 2025

Accounting Policies [Abstract]

Nature of Operations [Text Block]

NOTE 1 – NATURE OF OPERATIONS

IGC Pharma is on a mission to transform Alzheimer’s treatment. We are building a robust pipeline of drug candidates, each targeting different aspects of the disease. Our product candidate pipeline and anticipated milestones include the following: -

Asset		Target Indication		Mechanism of Action		Development Stage		Key Milestones
IGC- AD1		Agitation in Alzheimer’s dementia		CB1 receptor partial agonist; reduces neuroinflammation and restores neurotransmitter balance		Phase 2 clinical trial (CALMA study)		Interim Phase 2 data analysis suggests cognitive improvements in the active treatment group versus the placebo group,
TGR-63		Early to moderate Alzheimer’s disease		Disrupts amyloid-beta (Aβ) plaque formation; crosses blood-brain barrier		Preclinical		Demonstrated favorable safety profile; advancing towards clinical trials
LMP		Alzheimer’s disease		Targets neuroinflammation, neurotransmitter imbalance, and inflammasome-3		Preclinical		Bioequivalence to IGC-AD1 anticipated in 2025
IGC-M3		Early-stage Alzheimer’s disease		Inhibits Aβ plaque aggregation		Preclinical		Toxicology studies planned for mid-2025
IGC-1C		Alzheimer’s disease and metabolic disorders		Targets tau protein phase separation; potential GLP-1 receptor agonist		Preclinical		Exhibits strong binding affinity to tau protein; potential for weight loss applications
IGC-1A		Metabolic disorders (e.g., type 2 diabetes, obesity)		Potential GLP-1 and GIP receptor agonist; CB1 receptor inverse agonist		Preclinical		Identified through AI modeling; toxicology and dosing studies underway

This pipeline reflects IGC Pharma’s strategic focus on addressing neurodegenerative diseases, particularly Alzheimer’s, through innovative mechanisms targeting key pathological features like amyloid plaques and tau protein aggregation. Additionally, their expansion into metabolic disorders showcases the versatility of their drug discovery platform, leveraging artificial intelligence to identify promising therapeutic candidates.

As of March 31, 2025, the Company had the following operating subsidiaries: Techni Bharathi Private Limited (TBL), HH Processors, LLC, IGCare LLC, Sunday Seltzer LLC, IGC Pharma IP, LLC, IGC Pharma, LLC, SAN Holdings, LLC, Hamsa Biopharma India Pvt. Ltd. And Colombia-based beneficially-owned subsidiary IGC Pharma SAS. The Company’s fiscal year is the 52- or 53-week period that ends on March 31. The Company’ principal office is in Maryland established in 2005. Additionally, the Company has offices in Washington state, Colombia, South America, and India. The Company’s filings are available on www.sec.gov.

During fiscal 2025, the Company reassessed its reportable segment structure in connection with its strategic realignment toward Life Sciences. As a result, management determined that the Company operates as a single reportable segment, focused on the vision to make the world free from Alzheimer’s. Historically, the Company reported two operating segments: Life Sciences and Infrastructure. While the Infrastructure segment generated revenues in fiscal 2024, it did not generate any revenues in fiscal 2025 and is no longer actively managed or evaluated as a discrete operating segment by the Company’s Chief Operating Decision Maker. For more information, please refer to “Note 18 – Segment Information”.